By Mill Chart
Last update: Apr 8, 2024
Our stock screening tool has pinpointed BIOMARIN PHARMACEUTICAL INC (NASDAQ:BMRN) as a growth stock that isn't overvalued. NASDAQ:BMRN is excelling in various growth indicators while maintaining a solid financial footing. Furthermore, it remains attractively priced. Let's delve into the specifics below.
ChartMill employs its own Growth Rating system for all stocks. This score, ranging from 0 to 10, is derived by evaluating different growth factors, such as EPS and revenue growth, taking into account both past performance and future projections. NASDAQ:BMRN has earned a 7 for growth:
ChartMill assigns a Valuation Rating to each stock, ranging from 0 to 10. This rating is calculated by analyzing different valuation elements, such as price to earnings and free cash flow, both in absolute terms and relative to the market and industry. In the case of NASDAQ:BMRN, the assigned 6 reflects its valuation:
ChartMill assigns a Health Rating to every stock. This score ranges from 0 to 10 and evaluates the different health aspects like liquidity and solvency, both absolutely, but also relative to the industry peers. NASDAQ:BMRN scores a 5 out of 10:
ChartMill's Profitability Rating offers a unique perspective on stock analysis, providing scores from 0 to 10. These ratings consider a wide range of profitability metrics and margins, both in comparison to industry peers and on their own merits. For NASDAQ:BMRN, the assigned 7 is a significant indicator of profitability:
Every day, new Affordable Growth stocks can be found on ChartMill in our Affordable Growth screener.
For an up to date full fundamental analysis you can check the fundamental report of BMRN
This is not investing advice! The article highlights some of the observations at the time of writing, but you should always make your own analysis and invest based on your own insights.
BIOMARIN PHARMACEUTICAL INC
NASDAQ:BMRN (4/29/2024, 3:38:47 PM)
After market: 82.13 0 (0%)82.13
+1.22 (+1.51%)
Opportunistic investors can still find bargains, even with the Nasdaq Composite up 49% since the start of 2023.
Many fortunes have been made with a fortuitous investment in a biotech stock at the right time. That time might be now.
BMRN stock results show that Biomarin Pharmaceutical beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024.
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Biomarin Pharmaceutical (NASDAQ:BMRN) just reported results for the first quart...
First Quarter 2024 Total Revenues of $649 Million (+9% Y/Y and +13% at Constant Currency Y/Y); GAAP Diluted Earnings per Share (EPS) of $0.46 (+70% Y/Y) and...
/PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Alexander Hardy, President and Chief Executive Officer of BioMarin, will host...
Although the Nasdaq Composite is galloping to record highs, amazing deals among growth stocks can still be uncovered.
/PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced that positive early results from an investigator-sponsored Phase 2 study of VOXZOGO®...
/PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced today that Cristin Hubbard has been named executive vice president and chief commercial...
/PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced management is scheduled to participate in four upcoming investor conferences in...
The US Department of Justice has reportedly issued a subpoena to BioMarin Pharmaceutical (BRMN) seeking information related to sponsored testing programs for it